Yoshikawa K, Hashimoto T, Yamaguchi T, Dousei T, Moriguchi S, Taniguchi M, Ueda H, Taketani S, Utsumi T, Suhara H
Dept. of Surgery, Osaka Rosai Hospital.
Gan To Kagaku Ryoho. 1994 Mar;21(4):501-5.
The transfer of an orally administered anti-cancer agent, UFT, into the portal vein was examined in 21 patients with hepatic metastasis of colorectal cancer (synchronous metastasis in 9 and metachronous metastasis in 12 cases) encountered at our department. The time course of tegafur, 5-FU and uracil levels in portal blood was traced for maximum 6 hrs, starting 2 hrs after the final oral dose of UFT. The portal blood tegafur level was 11.89 +/- 4.31 micrograms/ml at 2 hrs after the final dose and decreased gradually thereafter, reaching to 8.48 +/- 8.42 micrograms/ml at 6 hrs after the final dose. Unlike the portal blood tegafur level, the portal blood 5-FU level did not show any similar tendency; it remained almost unchanged at 0.018 +/- 0.006 microgram/ml and approximately equal to the serum 5-FU level throughout the observation period.
在我科室收治的21例结直肠癌肝转移患者（其中9例为同时性转移，12例为异时性转移）中，研究了口服抗癌药优福定（UFT）向门静脉的转运情况。在最后一次口服UFT后2小时开始，对门静脉血中替加氟、5-氟尿嘧啶（5-FU）和尿嘧啶水平的时间进程进行了最长6小时的追踪。末次给药后2小时门静脉血中替加氟水平为11.89±4.31微克/毫升，此后逐渐下降，末次给药后6小时降至8.48±8.42微克/毫升。与门静脉血中替加氟水平不同，门静脉血中5-FU水平未表现出任何类似趋势；在整个观察期内，其在0.018±0.006微克/毫升几乎保持不变，且与血清5-FU水平大致相当。
